title: [An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
abstract: A-75 year-old man, diagnosed as ascending colon cancer with large bowel obstruction, multiple hepatic, lunge metastases and peritoneal dissemination, was treated with neoadjuvant chemotherapy (FOLFOX4: 2 courses) and subsequent ileocecal resection. Postoperative systemic chemotherapy with hepatic arterial infusion (HAI) of 5-FU was performed in the following fashion: FOLFOX4, FOLFIRI with or without bevacizumab or cetuximab was administered every 4 weeks and a weekly HAI twice every 4 weeks. By those treatments, the patient could maintain a 30-month long NC effect and a good performance status.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Health Medical Treatment Corporation Toshima Hospital.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ando
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nagahama
authors.forename: Akira
authors.initials: A
authors.lastname: Fukuda
authors.forename: Katunori
authors.initials: K
authors.lastname: Ami
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kurokawa
authors.forename: Kenichirou
authors.initials: K
authors.lastname: Hataji
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ganno
authors.forename: Norihito
authors.initials: N
authors.lastname: Kawasaki
authors.forename: Kuniyoshi
authors.initials: K
authors.lastname: Arai
authors.forename: Youichi
authors.initials: Y
authors.lastname: Okada
authors.forename: Shikofumi
authors.initials: S
authors.lastname: Tei
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin